New publication in JAMA Neurology! 🧠 In this study, led by @gsalvado.bsky.social, we developed and validated a plasma-based biological staging model for Alzheimer’s disease using two blood biomarkers: %p-tau217 and eMTBR-tau243. jamanetwork.com/journals/jam...

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease that closely mirrors an amyloid and tau positron emission tomography–based staging sy...

jamanetwork.com

New paper out in EMBO Mol Med! We use machine learning to predict Aβ-PET burden from fluid biomarkers. www.embopress.org/doi/full/10.... Key findings: - Performance R² = 0.79 - CSF Aβ42/Aβ40 most predictive of Aβ plaque presence - Plasma p-tau217 best for tracking increasing amyloid plaque burden

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid | EMBO Molecular Medicine

imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative Aβ-PET burden. Distinct contributions of soluble Aβ42/Aβ40 and plasma P-tau217 reveal their role in ...

embopress.org

🚨Postdoc position open at @BarcelonaBeta🚨 We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠 Fully funded position!!! More details: www.imim.cat/media/upload... Please share! #Alzheimer's #ENDALZ

🚨Paper alert🚨 New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals. jamanetwork.com/journals/jam... A 🧵...

Plasma P-Tau217 to Identify Preclinical AD

This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.

jamanetwork.com

🚨New publication in Nature Medicine! In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting. More details: linkedin.com/feed/update/... Full paper: www.nature.com/articles/s41...

Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers - Nature Medicine | The Swedish BioFINDER study

New publication in Nature Medicine!   In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...

linkedin.com

New paper published today in @nataging.nature.com ! This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data. A 🧵 below. #ENDALZ

@biofinder.bsky.social · last yr.

🚨New publication in Nature Aging🚨 Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social. We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages. nature.com/articles/s43... 🧵

Very grateful to have had the opportunity to share our work comparing the FDA-approved p-tau217/AB42 blood test to CSF!

Gemma Salvadó@gsalvado.bsky.social · last yr.

Super proud of @noellewarmenhoven.bsky.social ! She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦

‼️NEW PREPRINT‼️ What if you could take a normal 3T T1w MRI and make it look like it was acquired from a 7T scanner? That's exactly what we do using AI in our new preprint! Link: arxiv.org/abs/2507.13782 #neuroskyence #neurosky #compneuro #AI #datascience #neurology #mrisky #neuroimaging

New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @thelancetneuro.bsky.social: www.thelancet.com/journals/lan...

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study

Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associ...

thelancet.com

✨ REMINDER!! ✨ please help me gather the most inspiring papers of the last year (including your own!!) by completing the survey below! 🙏 Looking so much forward to presenting the @NeuroimagingPIA year in review talk at #AIC2025 in Toronto this July!! 🤩 alz.surveymonkey.com/r/923BTQK

@emmacoomans.bsky.social · last yr.

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠 🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this ~5min survey: alz.surveymonkey.com/r/923BTQK

How does the brain reorganize in the context of age and AD? Are functional changes in age and AD similar? Are these changes dynamic across the age/AD spectrum? We unpack these questions in a sample of N=973 with AD biomarkers Preprint: tinyurl.com/ymv8s7h8 ⬇️🧵 1/

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/

The preprint of my first PhD project is live! 🧠 Find the link to the manuscript and read about the key findings below. 👇 #alzheimersdisease #neuroimaging #tau #amyloid #mri #pet #biofinder

@biofinder.bsky.social · last yr.

‼️New preprint! We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other. Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇

A new, simpler and cheaper analytical method for the early detection of #Alzheimers disease could help bring #blood tests into the #healthcare system globally, according to a new study co-authored by @noellewarmenhoven.bsky.social from 🇸🇪 @lund-university.bsky.social.

Simple, yet effective way to early detect Alzheimer's disease

A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden.

healthcare-in-europe.com

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in @naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵

Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine

Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.

nature.com

‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social: 📖 www.nature.com/articles/s41... In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease - Nature Medicine

Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

nature.com

time.com/7273006/alzh...

An Alzheimer’s Blood Test Might Predict Advanced Disease

The test, which is not yet commercially available, focuses on a different form of the protein tau.

time.com